Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach

Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach

As breast cancer treatment options continue to evolve, biomarker and multigene assay testing are now considered a standard part of the clinical evaluation of estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER-2) negative breast carcinomas. These methodologies are used to...

Full description

Bibliographic Details
Main Authors: Bradley M. Turner, Hani Katerji, Huina Zhang, David G. Hicks
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:Human Pathology Reports
Subjects:
Biomarker
Multigene
Breast cancer
ER
Ki-67
HER-2
Online Access:http://www.sciencedirect.com/science/article/pii/S2772736X2100027X

Similar Items

Similar Items